Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

HC Wainwright & Co. Downgrades Y-mAbs Therapeutics to Neutral, Lowers Price Target to $8.6

Author: Benzinga Newsdesk | August 06, 2025 07:10am
HC Wainwright & Co. analyst Robert Burns downgrades Y-mAbs Therapeutics (NASDAQ:YMAB) from Buy to Neutral and lowers the price target from $11 to $8.6.

Posted In: YMAB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist